Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

Summary by biopharmadive.com
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.

1 Articles

biopharmadive.combiopharmadive.com
Center

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Monday, August 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Initial Public Offering (IPO) icon

Initial Public Offering (IPO)

CRISPR icon

CRISPR

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal